NF-jB is constitutively activated in adult T-cell leukemia (ATL) and is considered responsible for cell growth and prevention of cell death. In this study, we demonstrate that NF-jB is constitutively activated in various HTLV-1-infected T-cell lines and ATL-derived cell lines irrespectively of Tax expression as evidenced by the phosphorylation of IjBa and p65 subunit of NF-jB, activation of NF-jB DNA binding, and upregulation of various target genes including bcl-x L , bcl-2, XIAP, c-IAP1, survivin, cyclinD1, ICAM-1 and VCAM-1. The effects of a novel IjB kinase (IKK) inhibitor, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile (ACHP), were examined on cell growth of these cell lines and fresh ATL leukemic cells. We found that ACHP could inhibit the phosphorylation of IjBa and p65, as well as NF-jB DNA-binding, associated with downregulation of the NF-jB target genes and induce cell growth arrest and apoptosis in these cells. When Tax-active and Tax-inactive cell lines were compared, ACHP could preferentially inhibit cell growth of Tax-active cells. Moreover, ACHP exhibited strong apoptosis-inducing activity in fresh ATL cells. These findings indicate that ACHP and its derivatives are effective in inducing ATL cell death and thus feasible candidates for the treatment of ATL.
Introduction
Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disorder closely associated with the human T-cell leukemia virus type 1 (HTLV-1).
1,2 ATL arises after a long latent period of over 50 years and is considered to involve multi-step mechanism of tumorigenesis. 3 ATL is characterized by diffuse lymphadenopathy, hepatosplenomegaly, and infiltration of malignant cells into skin and other organs. 4 Acute type of ATL is an aggressive form of T-cell leukemia with a median survival of only 6 months and a projected 4-year survival of about 5%. Conventional chemotherapies appeared to be ineffective in prolonging the life of patients with ATL, mostly due to the frequent acquisition of drug resistance and adverse effects. Although novel clinical trials using interferon and arsenic trioxide or zidovudine exhibited better therapeutic responses, their efficacies were limited and only small percentages of patients achieved long-lasting remission. 5 Therefore, novel treatment modalities are desperately needed.
Recent studies have elucidated crucial roles of nuclear factorkB (NF-kB) in tumor development and progression. 6, 7 NF-kB is a transcription factor that regulates expression of various genes involved in cell cycle regulation and inhibition of apoptosis, such as cyclinD1, bcl-2, bcl-x L , XIAP, c-IAPs and survivin as well as genes involved in inflammatory and immune responses. 8 In addition, intracellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion molecule-1 (VCAM-1), which are not only important for cell adhesion but also for T-cell proliferation, are also under the control of NF-kB. 9 NF-kB is a hetero-or homodimer consisting of Rel family proteins, p65 (RelA), RelB, c-Rel, p105/p50 and p100/p52. 10 The p65/p50 heterodimer, a major form of NF-kB, is normally present in the cytoplasm in association with its inhibitor, IkBa. Stimulation by the inflammatory cytokines such as tumor necrosis factor a (TNFa) and interleukin-1b results in the activation of IkB kinase (IKK) complex through mitogen-activated protein kinase /extracellular signal-regulated kinase kinase 1,3 or NF-kB inducing kinase (NIK). IKKb serves as catalytic subunit that phosphorylates IkBa on two serine residues (Ser32/S36) (called 'canonical NF-kB activation pathway'). 11 On the other hand, IKKa is activated through NIK by alternative stimuli such as lymphotoxin b (LTb), B-cell activating factor and CD40 ligand, and mediates the processing of p100 to p52 ('noncanonical NF-kB activation pathway'). In addition, we have previously reported that phosphorylation of p65 at Ser 536 is crucial for NF-kB transcriptional activity and is mediated by IKKa upon LTb signaling. 12 Importantly, such non-canonical NF-kB activation cascade mediated by NIK-IKKa does not necessarily associate with phosphorylation of IkBa followed by its degradation. Thus, inhibitors for IkBa degradation may not be sufficient in inhibiting the NF-kB activity.
In ATL cells and HTLV-1-infected T-cells, a number of reports demonstrated the constitutive activation of NF-kB and its involvement in tumorigenesis. [13] [14] [15] These carcinogenic actions of HTLV-1 have been ascribed to Tax, a transactivator protein encoded by the virus, which is responsible for the activation of NF-kB. [16] [17] [18] For instance, Suzuki et al. 16 reported that Tax directly binds to and activates NF-kB. Tax is also known to activate NF-kB by stimulating IKK complex by interacting with IKKs. 17 Furthermore, Xiao et al. demonstrated that Tax promotes the proteolytic processing of p100. 18 In fresh ATL cells, however, NF-kB was shown to be constitutively activated although Tax is not expressed. 14, 15 As p52 expression is elevated in these cells, the involvement of the noncanonical NF-kB activation pathway is suggested in ATL cells. Thus, NF-kB plays a major role in ATL leukemogenesis and is considered to be a feasible target in the chemotherapy of ATL.
In this study, we confirmed the constitutive activation of NFkB in HTLV-1-infected T-cell and ATL cell lines and examined the effect of a novel IKK inhibitor, 2-amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-piperidin-4-yl nicotinonitrile (ACHP), on the growth and survival of HTLV- 19, 20 Here, we demonstrate that ACHP could efficiently induce cell growth arrest and apoptotic cell death by blocking NF-kB in ATL cells.
Materials and methods

Cells and reagents
HTLV-1-infected T-cell lines, ATL-35T, 21 81-66/45, 22 MJ, 23 and MT-2 23 cells, human ATL cell lines established from ATL patients, ATL-102, 24 ED-40515(À) 25 and TL-Om1 14 cells, and a HTLV-1-negative T-cell leukemia cell line Jurkat were used in this study. ED-40515 (À) and TL-Om1 cells were kind gifts from Drs M Maeda and M Matsuoka (Kyoto University, Japan). Fresh leukemia cells derived from acute-type ATL patients were obtained with informed consent from each patient at Nagoya City University Hospital and Imamura Bun-in Hospital after approval by the institutional ethical committee. All samples from ATL patients contained more than 80% leukemic cells. Peripheral blood mononuclear cells were derived from four healthy donors upon informed consent. All cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum at 371C in 5% CO 2 incubator. The novel IKK inhibitor, ACHP, 19, 20 was a kind gift from Drs T Murata and K B Bacon of Bayer Yakuhin Ltd (Kyoto, Japan).
Immunoblot analysis and antibodies
Immunoblot analyses were performed as previously described. 20 Briefly, 1.0 Â 10 6 cells were treated with or without ACHP. The cells were lysed in 50 ml of lysis buffer (20 mM HEPES-KOH (pH 7.9), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 5 mM NaF, 1 mM PMSF, 0.2% Triton X, protease inhibitor cocktail (Roche, Indianapolis, IN, USA)) and the supernatant was collected. Equal amounts of the proteins were electrophoresed on 10% SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with TBS-T (10 mM Tris-HCl (pH 8.0), 15 mM NaCl, 0.1% Tween) with 5% nonfat milk containing 1:1000 diluted primary antibodies against either phospho-IkBa (Ser32), phospho-p65 (Ser536), phospho-p65 (Ser276), phosphoAkt (Ser473), Akt, phospho-IKKa (Ser181), phospho-p38 MAPK (Thr180/Tyr182), phospho-ATF-2 (Thr71) and phospho-JNK (Thr183/Tyr185) (Cell Signaling Technology, Beverly, MA, USA), p65, p52/p100, IkB-a or a-tubulin (Santa Cruz, Santa Cruz, CA, USA). After incubation, the membranes were rinsed and further incubated with HRP-conjugated secondary antibodies (Amersham Biosciences, Buckinghamshire, UK) in TBS-T with 5% nonfat milk. Each protein was detected by SuperSignal (PIERCE, Rockford, IL, USA).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed as described previously. 20 Nuclear extracts were prepared from 1.0 Â 10 6 cells treated with or without ACHP. EMSA was performed using the nuclear extracts and the oligonucleotide probe containing NF-kB sequence in the promoter of HIV1-LTR. The sequence was as follows: 5 0 -TTT CTA GGG ACT TTC CGC CTG GGG ACT TTC CAG-3 0 . The DNA probe was 5 0 endlabeled using T4 polynucleotide kinase and [g-32 P] ATP (Amersham Biosciences). DNA binding reactions were performed at 301C for 15 min with labeled DNA probe and 15-30 mg protein of nuclear extract in 20 ml binding buffer (22 mM HEPES-KOH (pH7.9), 80 mM KCl, 5% glyceol, 0.1% NP-40, 1 mM dithiothreitol, 2 mg poly dI-dC, 2 g tRNA and protease inhibitor). The samples were subjected to electrophoresis on 5% nondenaturing polyacrylamide gel with 0.5 Â Tris-borate-EDTA buffer at 41C, followed by autoradiography. For competition and supershift analyses, nuclear extracts were preincubated with unlabeled probe DNA and antibodies (4 mg) against p65, RelB, c-Rel, p52 or p50 (Santa Cruz), respectively, for 30 min at 301C.
Reverse transcription-PCR
Reverse transcription-PCR (RT-PCR) was performed as described previously. 20 Total RNA was prepared from 1.0 Â 10 6 cells. After incubation with DNase I (Invitrogen, Carlsbad, CA, USA), RNA was reverse transcribed using SuperScript System (Invitrogen). Each sample was subjected to PCR amplification, and the products were analyzed by 1% agarose gel electrophoresis. The oligonucleotide primers for bcl-2, cyclinD1, XIAP, cIAP-1 and b-actin, were used as described previously. 20 The primers for bcl-x L and survivin were as follows: bcl-x L sense,
Growth inhibition assay
Approximately 1.5 Â 10 4 cells were cultured in 96-well plate in triplicates at 371C. Growth inhibitory effect of ACHP was determined using MTT assay as previously described. 20 Optical densities (OD) at 570 and 630 nm were measured with multiplate reader. Cell viability (%) was calculated as follows: (OD 630 -OD 570 of the samples/OD 630 -OD 570 of the control) Â 100 (%).
Flowcytometric analysis
The flowcytometric analyses were performed using FACSCAN (BD Bioscience, San Jose, CA, USA) and CellQuest program as previously described. 20 For cell cycle analysis, cells were incubated with propiodium iodide (PI) (Sigma). For apoptosis analysis, cells were incubated with fluorescein isothiocynate (FITC)-conjugated annexinV (MBL, Nagoya, Japan). For ICAM-1 and VCAM-1 expression analysis, cells were incubated with phycoerythrin (PE)-conjugated mouse antibody against human ICAM-1 or VCAM-1, or isotype matched control IgG (BD Biosciences).
Results
Constitutive NF-kB activation in HTLV-1-infected T-cell lines and ATL cell lines
In order to analyze the NF-kB signaling in HTLV-1-infected T-cell lines and ATL cell lines, we examined the phosphorylation status of IkBa and p65. ATL-35T, 81-66/45, MJ, MT-2 and ATL-102 cells are known to express Tax ('Tax-active'), whereas ED-40515(À) and TL-Om1 cells are known not to express Tax ('Tax-inactive'). 14, [21] [22] [23] [24] [25] As shown in Figure 1a , the phosphorylation of IkBa at Ser32 and p65 at Ser536 were detected in all cell lines except Jurkat, a control T-cell line, in the absence of any stimuli. We also detected prominent band of p100/p52 in five Tax-active cell lines, but not in Tax-inactive and control cell lines. The phosphorylation of p65 at Ser 276, which is not mediated by IKK, 26 was not correlated with IkBa phosphorylation. Constitutive phosphorylation of Akt at Ser473 was observed in five Tax-active cell lines and Jurkat.
We then performed EMSA using specific probes containing NF-kB binding sequence in the HIV-1 LTR promoter. The results revealed that NF-kB was constitutively activated in these HTLV-1-infected T-cell lines and ATL-derived cell lines, but not in Jurkat cells (Figures 1b and 2d) . Representative results of MT-2 (Taxactive) and ED-40515 (À) (Tax-inactive) cells are shown in Figure 1b . Figure 1b also shows the result of supershift analysis using competitive antibody against each NF-kB subunit. In both cells, constitutive DNA binding of NF-kB was detected without any stimuli, and supershift bands were observed by addition of antibodies against p65, p52 or p50, indicating that activated NF-kB consisted of p65, p52 and p50 but not RelB or c-Rel.
Inhibitory effects of ACHP on NF-kB activation
We then examined the inhibitory effect of ACHP, a specific inhibitor for IKKb and IKKa, on the phosphorylation of IkBa and p65 in these cell lines. Representative results are shown in In Figure 2c , the inhibitory effect of ACHP on other kinases involved in NF-kB pathways and other major signal transduction pathways are shown. ACHP showed no effect on phosphorylation of IKKa at Ser 181, processing of p100/p52, or phosphorylation of p65 at Ser 276. Moreover, ACHP did not inhibit the phosphorylation of p38 MAPK, ATF-2 and JNK. Unexpectedly, ACHP inhibited the phosphorylation of Akt (IC 50 values were 4.5 mM. See the Supplementary Information), which is presumably responsible for the cytotoxic effect of ACHP on Jurkat cell survival. In Figure 2d , the inhibitory effect of ACHP on the DNAbinding activity of NF-kB was examined in MT-2, ED-40515(À) and Jurkat cells, using specific probes containing NF-kB binding sequence in the HIV-1 LTR promoter. In MT-2 cells, the NF-kB DNA binding was decreased by ACHP at greater than 1 mM. On the other hand, in ED-40515(À) cells, where the NF-kB DNA binding was weaker than MT-2, the significant inhibitory effect of ACHP was not observed until 50 mM.
Inhibitory effect of ACHP on expression of NF-kB target genes
In ATL, constitutive transcription of antiapoptotic genes such as bcl-x L , XIAP, c-IAPs and survivin has been reported and ascribed to the resistance against anticancer agents.
27,28 NF-kB is known to be involved in the proliferation of HTLV-1-infected cell lines and fresh ATL cells by upregulating growth-promoting genes such as cyclin D1. 29 In addition, NF-kB stimulates the expression of ICAM-1 and VCAM-1 genes, which mediate T-cell activation and proliferation. 9, 30 As shown in Figure 3a , a distinct inhibition of cyclin D1 gene expression was observed in MT-2 and ED-40515 (À) cells. Inhibition of bcl-x L , bcl-2, XIAP, c-IAP1 and survivin gene expressions was observed at high concentration of ACHP. These findings were also reproducibly observed using quantitative real-time RT-PCR analysis (data not shown), although we do not currently know the reason of the different susceptibilities of individual genes to ACHP. In Jurkat cells, inhibition of these gene expressions was weaker than ATL cell lines even at high concentration of ACHP. Figure 3b and c demonstrate that ICAM-1 and VCAM-1are highly expressed in MT-2 and ATL-102 cells, and that significant inhibitory effect was evident even at 1 mM ACHP. Whereas ACHP downregulated the expression of VCAM-1 
Suppression of cell cycle progression and induction of apoptosis by ACHP
As shown in Figure 4a , ACHP reduced the fraction of cells at S phase in MT-2 and ED-40515 (À) cells, whereas no effect was observed in control Jurkat cells. These findings indicate that ACHP inhibits the growth of HTLV-1-infected T-cell lines in which NF-kB is constitutively activated. In Figure 4b , the number of cells undergoing apoptosis (annexinV-positive) was measured. In all HTLV-1-infected T-cell cell lines, apoptosis induction was remarkably observed at 50 mM, after 8 h treatment with ACHP. In addition, ACHP induced the cleavage of PARP in MT-2 and ED-40515 (À) cells (data not shown). We then examined the effects of ACHP on the growth of seven HTLV-1-infected T-cell lines and a control noninfected T-cell line (Jurkat). As shown in Figure 4c , ACHP inhibited the growth of these cells in a dose-dependent manner. Tax-active cell lines were more susceptible to ACHP than Tax-inactive cell lines and Jurkat (IC 50 values in Tax-active cell lines, Tax-inactive cell lines or Jurkat were 3.171.3 mM, 10.771.7 mM and 23.6 mM, respectively), suggesting that the growth of Tax-active cells depends on NF-kB more than Tax-inactive cells. These observations are consistent with augmented NF-kB DNA binding and accelerated turn over of IkBa in Tax-active cells (Figures 1 and 2 ).
Growth inhibition and apoptosis induction of fresh ATL cells by ACHP
We then evaluated the effects of ACHP on the growth of fresh ATL cells obtained from four independent acute-type ATL patients. Peripheral blood mononuclear cells (PBMCs) contained greater than 90% leukemic cells. Control PBMCs were similarly obtained from four healthy individuals. As shown in We then examined the levels of IkBa and p65 phosphorylation, as well as the NF-kB DNA binding, of fresh ATL cells and their susceptibility to ACHP-mediated apoptosis. As shown in Figure 5b , constitutive phosphorylation of p65 at Ser 536 and NF-kB DNA binding were observed and inhibited by ACHP (IC 50 value: 0.6 mM), however, phosphorylation of IkBa at Ser 32 was not detected in fresh ATL cells. Identical results of protein phosphorylation were observed with other fresh ATL cells, whereas no constitutive phosphorylation of p65 and IkBa was observed with control PBMCs (data not shown). The flowcytometric analysis of fresh ATL cells (Figure 5c ) revealed the appearance of prominent sub G 0 /G 1 population suggesting the presence of cells undergoing apoptosis upon treatment with ACHP. Consistently, annexinV-positive cells were detected even 
Discussion
In this study, we demonstrated that a novel IKK inhibitor, ACHP, efficiently inhibited NF-kB that is constitutively activated in ATL cell lines and fresh ATL cells. We also observed that it could block their growth by inducing apoptosis and cell cycle arrest. The constitutive activation of NF-kB has been reported in other neoplasms such as colorectal cancer, hepatocellular carcinoma, multiple myeloma and various forms of malignant lymphoma. 6, 7, 20 In these neoplasms, NF-kB was shown to be involved in tumorigenesis and disease progression by upregulating antiapoptotic proteins, cell cycle regulators, and cell adhesion molecules. In fact, inhibitors of NF-kB such as Bay11- 7082 13 showed antitumor effects. In addition, we have previously reported the growth inhibitory effect of ACHP on multiple myeloma cell lines and the synergism with conventional chemotherapeutic agents. 20 We observed the growth inhibitory effect of ACHP especially in Tax-active HTLV-1-infected T-cell lines. In MT-2 cells, for example, the NF-kB DNA binding was prominent and was efficiently inhibited by ACHP (Figure 2d ). On the other hand, in Tax-inactive cell lines such as ED-40515(À), phosphorylation of IkBa/p65 and NF-kB DNA binding was not inhibited until higher concentration (greater than 10 mM) of ACHP was used (Figure 2a and d). It was noted that the effective ACHP concentrations in blocking the phosphorylation and NF-kB DNA binding in these cell lines correlated with the extents of growth inhibition by ACHP (Figure 4c ). Similar observations were reported by Mori et al. 13 where Tax-active HTLV-1-infected T-cell lines were more susceptible to the growth inhibitory effect of Bay 11-7082, another inhibitor of IKK, than Tax-inactive ATL cell lines.
The functional interaction between Tax and NF-kB activation pathway has been well investigated in previous studies by others. [16] [17] [18] In addition, constitutive activation of NF-kB is also reported in Tax-independent ATL cells 14, 15 although the mechanism is not established yet. In these cells, it is postulated that the overexpression of TNFa or LTb, which is often found in ATL patients, 22, 31 could substitute the effects of Tax. We have demonstrated that LTb receptor-mediated signaling specifically involves IKKa and induces p65 phosphorylation at Ser 536. 12 The constitutive phosphorylation of p65 at Ser 536 was evident in HTLV-1-infected T-cell lines irrespectively of the expression of functional Tax (Figure 1 ). In support of this possibility, Hironaka et al. 15 reported that dominant-negative IKKa mutant, but not dominant-negative IKKb mutant, could inhibit the NF-kB activity in ATL-derived cell lines. Interestingly, we observed the NF-kB DNA binding associated with the constitutive p65 Ser 536 phosphorylation but not with the IkBa phosphorylation in fresh ATL samples (Figure 5b ). In these cells, even lower concentrations of ACHP could induce apoptosis and cell growth arrest as compared with ATL cell lines (Figures 5c and d) . These findings collectively suggest that the IKKa-mediated NF-kB activation pathway may play a crucial role in ATL. In this study, we observed that various NF-kB target genes showed different susceptibility to the inhibitory effects of ACHP (Figure 3 ). For example, whereas expression of ICAM-1 and VCAM-1 was inhibited by the low dose of ACHP (Figure 3b and  c) , expression of anti-apoptotic genes, such as bcl-XL, bcl-2, XIAP, c-IAP2 and survivin, required higher doses of ACHP (Figure 3a) . It is possible that various NF-kB target genes are regulated by distinct NF-kB activation pathways. In this context, we found that IkBa phosphorylation, primarily catalyzed by IKKb, was inhibited by low dose ACHP in HTLV-1-infected T cell lines (Figure 2) . Thus, it appears that the ACHP-mediated inhibition of NF-kB target genes favors the canonical activation pathway. In addition, we found that ACHP could also induce apoptosis in Jurkat cells unexpectedly (Figure 2c ) because no constitutive NF-kB activation was detected in these cells (Figures 1 and 2) . In Jurkat cells the genetic defect of PTEN phosphatase is considered responsible for the cellular transformation. 32 The genetic defect of PTEN causes the constitutive Akt phosphorylation mediated by phosphatidylinositol-3 phosphate kinase (PI3K) and its inhibition by ACHP may have caused cell death in Jurkat. The constitutive Akt phosphorylation is also observed in the Tax-active cell lines (Figure 1a ). Thus, it is possible that net effects of ACHP in inhibiting the growth of ATL cell lines may be through IKK-NF-kB and PI3K-Akt kinase pathways.
In conclusion, our results indicate the therapeutic efficacy of ACHP and its derivatives in the treatment of ATL by blocking the signal transduction pathway leading to constitutive activation of NF-kB, as well as Akt phosphorylation. Additionally, we observed the apparent differences in the NF-kB activation pathways involved in Tax-active, Tax-inactive, and most notably, fresh ATL cells and highlighted the role of IKKa in ATL leukemogenesis. Thus, ACHP and its derivatives could be feasible components of the novel anti-ATL chemotherapeutic regimen by sensitizing leukemic cells to the conventional cytotoxic agents.
